Established to support development of new drugs and genetic treatments by enabling geographically widespread clinical trials, Marken's core business is bringing investigational medicinal product (IMP), testing kits and samples to and from trial participants under scientifically critical, controlled transport conditions. This often requires extremely challenging delivery time and temperature management constraints..
The material ESG risks outlined below reflects the fact that our operations involve collection, storage and protection of personal information, as well as drugs, blood and other biological samples. The essential need for air transport and energy intensive refrigeration necessitates high emission per shipment, and resource intensive reusable or single use packaging.
While focused primarily around meeting the core clinical trial needs of our leading multinational pharmaceutical clients, Marken's unique skills sets are also called upon at times to meet other precision healthcare logistical challenges. These range from managing the impact of armed conflict on essential drug deliveries to enabling logistically challenging, philanthropically funded medical research in low-income countries or biological sample collection for large scale environmental research (see the case study at the end of this Report).
As such, our contribution to human wellbeing is not only enabling mainstream development of new medical cures and treatments, but also in efforts to reduce infant mortality rates and the burden of avoidable diseases in the world’s most vulnerable communities and to monitor and remediate environmental impacts of human activities.